Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06609239 · ClinicalTrials.gov registry record · Phase 2
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma.
A Phase 2 study of Asthma, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 900
- Enrollment target
- 20
- Study locations
NCT06609239 is a Phase 2 study of Asthma that is actively recruiting participants, run by Sanofi. The registered enrollment target is 900 participants, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT06609239, a Phase 2 study of Asthma, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 900 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2, open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with asthma who have previously completed the parent studies. After completion of the parent study, eligible participants will be offered the opportunity to participate in the long-term extension (LTE) study with lunsekimig. The study duration will be up to 100 weeks with a treatment duration being up to 96 weeks.
Conditions Studied
Interventions
- DRUG Lunsekimig
Study Locations (20)
Florida
- Helix Biomedics- Site Number : 8400114 - Boynton Beach
- Beautiful Minds Clinical Research Center- Site Number : 8400049 - Cutler Bay
- Qway Research - Hialeah- Site Number : 8400015 - Hialeah
- Clintex Research Group - Miami - Southwest 27th Avenue- Site Number : 8400048 - Miami
- High Quality Research- Site Number : 8400039 - Miami
- Innovations Biotech- Site Number : 8400040 - Miami
- New Access Medical Center- Site Number : 8400043 - Miami
- Deluxe Health Center- Site Number : 8400045 - Miami Lakes
- Windom Allergy, Asthma and Sinus Specialists- Site Number : 8400019 - Sarasota
Texas
- Orion Clinical Research- Site Number : 8400001 - Austin
- South Texas Medical Research Institute - TTS Research- Site Number : 8400010 - Boerne
- Baylor University Medical Center- Site Number : 8400002 - Dallas
Colorado
- Allianz Research Institute - Aurora- Site Number : 8400026 - Aurora
- Western States Clinical Research- Site Number : 8400014 - Wheat Ridge
Michigan
- University of Michigan Health System - Ann Arbor- Site Number : 8400004 - Ann Arbor
Missouri
- Midwest Clinical Research Center - St. Louis- Site Number : 8400006 - St Louis
North Carolina
- Tryon Medical Partners - Charlotte - Piedmont Row Drive South- Site Number : 8400029 - Charlotte
Ohio
- Asthma & Allergy Center - Toledo- Site Number : 8400017 - Toledo
Oklahoma
- OK Clinical Research- Site Number : 8400021 - Edmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2031-01-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06609239
The ClinicalTrials.gov registry entry for NCT06609239 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (42% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Lunsekimig is the first listed.
NCT06609239 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, Texas, Colorado.
Frequently Asked Questions
What is clinical trial NCT06609239 about?
NCT06609239 is a clinical study titled "Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma.". This is a phase 2, open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with asthma who have previously completed the parent studies. After completion of the parent study, eligible participants will be offered the opportunity to participate in ...
What is the current status of trial NCT06609239?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 900 participants. The study started on 2024-09-30. Estimated completion is 2031-01-20.
What conditions does trial NCT06609239 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT06609239?
The interventions under investigation include: Lunsekimig (DRUG).
Who is sponsoring clinical trial NCT06609239?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06609239 being conducted?
This trial has 20 study locations across Colorado, Florida, Michigan, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.